At the proteome level, these species may perturb protein homeostasis, as they contain nucleophilic groups such as aldehydes, ketones and epoxides that can generate advanced lipoxidation end products, by forming adducts with proteins in a process called lipoxidation ( A closely related form of lipotoxicity is associated with the dysregulation of lipid droplets (Olzmann and Carvalho, 2019)
Medicare: Does not cover either medication for weight loss under Part D (statutory exclusion of weight-loss drugs) Covers Mounjaro (tirzepatide for diabetes) and Ozempic (semaglutide for diabetes) under Part D Some Medicare Advantage plans cover Wegovy or Zepbound, but this is plan-specific Commercial insurance: Wegovy coverage: approximately 35% of commercial plans cover with prior authorization (as of Q1 2026) Zepbound coverage: approximately 28% of commercial plans cover with prior authorization Prior authorization typically requires documented BMI 30 (or 27 with comorbidity), previous weight-loss attempt, and prescriber attestation Cash prices (as of April 2026): Wegovy: $1,349 per month (list price) Zepbound: $1,059 per month (list price) Manufacturer savings programs reduce out-of-pocket costs for commercially insured patients but do not apply to Medicare, Medicaid, or uninsured patients in most states
Alongside medication, integrating lifestyle changes is essential for optimal results
CamposHODrummondLRRodriguesQTMachadoFSPiresWWannerSPet al
Unlike some earlier candidates that predominantly activated G-protein or arrestin pathways asymmetrically, tirzepatide demonstrates relatively balanced downstream signaling at both targets
Approved medications can be widely distributed and prescribed by healthcare providers, ensuring that patients have access to effective treatments
